New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 21, 2012
09:59 EDTFANG, NRGM, HTWR, AMX, EXXI, HRL, EV, STJ, HPQ, CBSHOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: America Movil (AMX) downgraded to Neutral from Buy at Citigroup... Commerce Bancshares (CBSH) downgraded to Underweight from Equal Weight at Morgan Stanley... Eaton Vance (EV) downgraded to Sell from Neutral at Citigroup... HeartWare (HTWR) downgraded to Market Perform from Outperform at Wells Fargo... Hewlett-Packard (HPQ) downgraded to Sector Perform from Outperform at RBC Capital... Hewlett-Packard (HPQ) downgraded to Underperform from Neutral at Mizuho... Hormel Foods (HRL) downgraded to Underperform from Outperform at CLSA... Inergy Midstream (NRGM) downgraded to Neutral from Outperform at RW Baird... St. Jude Medical (STJ) downgraded to Market Perform from Outperform at Wells Fargo.... Energy XXI (EXXI) initiated with a Buy at Ladenburg... Diamondback Energy (FANG) intiated with an Add at Capital One.
News For AMX;CBSH;EV;HTWR;HPQ;HRL;NRGM;STJ;EXXI;FANG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
May 20, 2015
06:40 EDTHRLHormel Foods sees avian influenza impact on Jennie-O Turkey sales "significant"
Subscribe for More Information
06:37 EDTHRLHormel Foods backs FY15 non-GAAP view at lower end of $2.50-$2.60
Subscribe for More Information
06:35 EDTHRLHormel Foods reports Q2 EPS 67c, consensus 63c
Subscribe for More Information
05:29 EDTSTJSt. Jude Medical announces preliminary results from ILUMIEN I and ILUMIEN II
St. Jude Medical announced preliminary results from the ILUMIEN I trial and final results from the ILUMIEN II clinical study. Taken together, the findings from both studies show that with resolution up to 10 times higher than intravascular ultrasound, optical coherence tomography imaging can help improve stent selection and deployment, better support clinical decision-making and improve patient outcomes. In the prospective study to date examining OCTís impact on clinical decisions and their associated outcomes, ILUMIEN I assessed 418 patients suffering stable or unstable angina or non-ST segment elevation myocardial infarction. The studyís 12-month data shows: OCT guidance conducted either pre- or post-PCI altered physician decision-making in 65% of patients; Pre-PCI OCT altered treatment planning in 55% of patients and led to changes in decisions related to stent length and diameter; OCT imaging was associated with a reduction of in-hospital MI when used pre- and post-PCI to change the procedural strategy. The ILUMIEN II study was designed to determine whether OCT guidance results in a comparable degree of stent expansion as IVUS imaging. After an analysis of OCT-guided stenting or IVUS-guided stenting in 940 patients from the ILUMIEN I and ADAPT-DES studies, the degree of stent expansion was found to be comparable between OCT and IVUS imaging. The studyís data shows OCT and IVUS guidance were also associated with comparable rates of major stent malapposition, tissue protrusion and stent edge dissection.
May 19, 2015
15:10 EDTHRLHormel Foods technical notes before earnings
Subscribe for More Information
15:00 EDTHRL, EVNotable companies reporting before tomorrow's open
Subscribe for More Information
12:55 EDTHPQPC related stocks struggle after Morgan Stanley says PC turn won't come until Q3
Subscribe for More Information
08:05 EDTSTJSt. Jude Medical announces Canadian launch of Prodigy Chronic Pain System
Subscribe for More Information
07:31 EDTEXXIUBS to hold a conference
Subscribe for More Information
06:36 EDTHPQHP sued by MicroTech for $16.5M for 'unfairly taking advantage'
In a lawsuit filed Monday with the United States District Court for the Northern District of California in San Francisco, Virginia technology company MicroTech accuses Hewlett Packard and the software maker it now owns, Autonomy, of unfairly taking advantage by refusing to return $16.5M in cash paid to Autonomy for software never delivered in a fashion where it could be re-sold. During a national telephonic press conference, Lanny J. Davis, a Washington, D.C. attorney advising MicroTech, described the core allegation in the breach of contract case filed against HP: "Regardless of whether HP was defrauded by Autonomy, or whether HP's over-payment for Autonomy was a product of a possible due diligence failure, in my opinion, HP is not entitled to keep both MicroTech's money AND Autonomy's software that MicroTech duly purchased," Davis said.
06:24 EDTHPQHP to sell controlling stake in H3C unit to Tsinghua Unigroup, Reuters reports
HP will sell its 51% stake in H3C, its China-based computing unit, to Tsinghua Unigroup, Reuters reports, citing comments from a spokesperson for the Chinese private-equity fund's parent company. Terms have not been disclosed, but the spokesperson says he believes the deal will be completed in the coming days. Reference Link
May 18, 2015
14:15 EDTHPQHewlett-Packard volatility elevated into Q2 and outlook
Subscribe for More Information
07:57 EDTFANGTopeka highlights potential E&P takeover targets
Topeka continues to believe that the E&P companies most likely to be acquired are situated in the core areas in the Permian, Eagle Ford, Bakken, Niobrara and Marcellus/Utica. The firm highlights Cabot Oil & Gas (COG), Energen (EGN), Diamondback Energy (FANG), Gulfport Energy (GPOR), Laredo Petroleum (LPI), Magnum Hunter (MHR) and Oasis Petroleum (OAS) as potential takeout targets. It keeps Buy ratings on all the stocks named.
May 15, 2015
14:20 EDTSTJSt. Jude Medical reports positive results from CardioMEMS HF System
Subscribe for More Information
14:01 EDTSTJSt. Jude Medical reports positive results from Allure Quadra CRT-P System
St. Jude Medical announced the presentation of important data supporting the first and only quadripolar cardiac resynchronization therapy pacemaker system in the U.S., during the Heart Rhythm Society's 36th annual scientific sessions. The Allure Quadra CRT-P system, with the Quartet Quadripolar LV Lead is associated with a 63% reduction in the need to replace the lead or deactivate CRT following implant. Quadripolar LV pacing using SJM quadripolar CRT-Ds or CRT-Ps and an SJM quadripolar lead provides physicians with multiple pacing options to avoid phrenic nerve stimulation and allow for optimal treatment delivery without the need to replace or deactivate the therapy. An analysis evaluating more than 3,000 patients implanted with a CRT-P (1,325 with a quadripolar lead vs. 1,930 with a bipolar lead) looked at whether the known decreased need to replace or deactivate LV leads associated with SJM quadripolar CRT-Ds and the Quartet LV lead also extends to St. Jude Medical quadripolar CRT-Ps. The retrospective data analysis was presented in a session titled Quadripolar Leads are Associated with Fewer LV Lead Replacements and Deactivations in CRT-P Patients by Dr. Mintu P. Turakhia, who led the investigation. The data show that patients with the Quartet LV lead were 63% less likely to undergo lead replacement or deactivation of CRT compared to the patients with bipolar leads.
11:00 EDTHPQHewlett-Packard volatility elevated into Q2 and outlook
Subscribe for More Information
08:45 EDTSTJSt. Jude Medical management to meet with Leerink
Subscribe for More Information
08:41 EDTSTJSt. Jude Medical management to meet with Leerink
Subscribe for More Information
07:40 EDTHPQHP split to be positive catalyst, says Deutsche Bank
Deutsche Bank believes HP's split will be a positive catalyst for shares this year. It views the stock as attractively priced ahead of the Q2 results on May 21 and says HP remains a top pick for 2015. Deutsche has a Buy rating on the name with a $45 price target.
07:09 EDTFANGHayman Capital gives quarterly update on stakes
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use